- Section 1 Patients and their treatment
- Section 2 Background to medicine
- Section 3 Cell biology
- Section 4 Immunological mechanisms
- Section 5 Principles of clinical oncology
- Section 6 Old age medicine
- Section 7 Pain and palliative care
- Section 8 Infectious diseases
- Section 9 Sexually transmitted diseases
- Section 10 Environmental medicine, occupational medicine, and poisoning
- Section 11 Nutrition
- Section 12 Metabolic disorders
- Section 13 Endocrine disorders
- Section 14 Medical disorders in pregnancy
- Section 15 Gastroenterological disorders
- Section 16 Cardiovascular disorders
- Section 17 Critical care medicine
- Section 18 Respiratory disorders
- 18.1 Structure and function
- 18.2 The clinical presentation of respiratory disease
- 18.3 Clinical investigation of respiratory disorders
- 18.4 Respiratory infection
- 18.5 The upper respiratory tract
- 18.6 Allergic rhinitis
- 18.7 Asthma
- 18.8 Chronic obstructive pulmonary disease
- 18.9 Bronchiectasis
- 18.10 Cystic fibrosis
- 18.11 Diffuse parenchymal lung diseases
- 18.12 Sarcoidosis
- 18.13 Pneumoconioses
- 18.14 Miscellaneous conditions
- 18.14.1 Diffuse alveolar haemorrhage
- 18.14.2 Eosinophilic pneumonia
- 18.14.3 Lymphocytic infiltrations of the lung
- 18.14.4 Hypersensitivity pneumonitis
- 18.14.5 Pulmonary Langerhans’ cell histiocytosis
- 18.14.6 Lymphangioleiomyomatosis
- 18.14.7 Pulmonary alveolar proteinosis
- 18.14.8 Pulmonary amyloidosis
- 18.14.9 Lipoid (lipid) pneumonia
- 18.14.10 Pulmonary alveolar microlithiasis
- 18.14.11 Toxic gases and aerosols
- 18.14.12 Radiation pneumonitis
- 18.14.13 Drug-induced lung disease
- 18.15 Chronic respiratory failure
- 18.16 Lung transplantation
- 18.17 Pleural diseases
- 18.18 Disorders of the thoracic cage and diaphragm
- 18.19 Malignant diseases
- Section 19 Rheumatological disorders
- Section 20 Disorders of the skeleton
- Section 21 Disorders of the kidney and urinary tract
- Section 22 Haematological disorders
- Section 23 Disorders of the skin
- Section 24 Neurological disorders
- Section 25 Disorders of the eye
- Section 26 Psychiatric and drug-related disorders
- Section 27 Forensic medicine
- Section 28 Sport and exercise medicine
- Section 29 Biochemistry in medicine
- Section 30 Acute medicine
Pulmonary alveolar proteinosis
- Chapter:
- Pulmonary alveolar proteinosis
- Author(s):
S. J. Bourke
- DOI:
- 10.1093/med/9780198746690.003.0427
In 90% of cases pulmonary alveolar proteinosis is caused by autoimmune antibodies to GM-CSF which impair the function of alveolar macrophages in clearing surfactant from the alveoli, giving rise to impaired gas exchange, breathlessness, and respiratory failure. Chest radiography shows extensive alveolar shadowing simulating pulmonary oedema, and CT scanning shows a characteristic ‘crazy paving’ pattern. The presence of GM-CSF antibodies in the serum is useful in diagnosis. Bronchoalveolar lavage or lung biopsy demonstrates alveolar secretions that are strongly PAS-positive. Treatment is by physical removal of the lipoproteinaceous material from the alveoli by whole-lung lavage. Massive inhalation of dust and fumes may overwhelm macrophage function, giving rise to secondary pulmonary alveolar proteinosis.
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- Section 1 Patients and their treatment
- Section 2 Background to medicine
- Section 3 Cell biology
- Section 4 Immunological mechanisms
- Section 5 Principles of clinical oncology
- Section 6 Old age medicine
- Section 7 Pain and palliative care
- Section 8 Infectious diseases
- Section 9 Sexually transmitted diseases
- Section 10 Environmental medicine, occupational medicine, and poisoning
- Section 11 Nutrition
- Section 12 Metabolic disorders
- Section 13 Endocrine disorders
- Section 14 Medical disorders in pregnancy
- Section 15 Gastroenterological disorders
- Section 16 Cardiovascular disorders
- Section 17 Critical care medicine
- Section 18 Respiratory disorders
- 18.1 Structure and function
- 18.2 The clinical presentation of respiratory disease
- 18.3 Clinical investigation of respiratory disorders
- 18.4 Respiratory infection
- 18.5 The upper respiratory tract
- 18.6 Allergic rhinitis
- 18.7 Asthma
- 18.8 Chronic obstructive pulmonary disease
- 18.9 Bronchiectasis
- 18.10 Cystic fibrosis
- 18.11 Diffuse parenchymal lung diseases
- 18.12 Sarcoidosis
- 18.13 Pneumoconioses
- 18.14 Miscellaneous conditions
- 18.14.1 Diffuse alveolar haemorrhage
- 18.14.2 Eosinophilic pneumonia
- 18.14.3 Lymphocytic infiltrations of the lung
- 18.14.4 Hypersensitivity pneumonitis
- 18.14.5 Pulmonary Langerhans’ cell histiocytosis
- 18.14.6 Lymphangioleiomyomatosis
- 18.14.7 Pulmonary alveolar proteinosis
- 18.14.8 Pulmonary amyloidosis
- 18.14.9 Lipoid (lipid) pneumonia
- 18.14.10 Pulmonary alveolar microlithiasis
- 18.14.11 Toxic gases and aerosols
- 18.14.12 Radiation pneumonitis
- 18.14.13 Drug-induced lung disease
- 18.15 Chronic respiratory failure
- 18.16 Lung transplantation
- 18.17 Pleural diseases
- 18.18 Disorders of the thoracic cage and diaphragm
- 18.19 Malignant diseases
- Section 19 Rheumatological disorders
- Section 20 Disorders of the skeleton
- Section 21 Disorders of the kidney and urinary tract
- Section 22 Haematological disorders
- Section 23 Disorders of the skin
- Section 24 Neurological disorders
- Section 25 Disorders of the eye
- Section 26 Psychiatric and drug-related disorders
- Section 27 Forensic medicine
- Section 28 Sport and exercise medicine
- Section 29 Biochemistry in medicine
- Section 30 Acute medicine